Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-722 · 5 trials · 2 indications
Cmax of ABBV-722
Tmax of ABBV-722
AUCt of ABBV-722
AUCinf of ABBV-722
β of ABBV-722
t1/2 of ABBV-722
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax,ss of ABBV-722
Tmax of ABBV-722
AUCtau,ss of ABBV-722
Ctrough,ss of ABBV-722
Cmax,ss of Upadacitinib
Tmax of Upadacitinib
AUCtau,ss of Upadacitinib
Ctrough,ss of Upadacitinib
Safety evaluations will include AE monitoring, vital sign measurements (including orthostatic blood pressure and pulse rate), ECG variables, and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration. Clinically significant abnormal changes in physical examination findings will be reported as AEs.
Cmax of ABBV-722.
AUCt of ABBV-722.
AUCinf of ABBV-722
Ctrough of ABBV-722.
AUC from AUCtau following the first and last doses of ABBV-722.
Beta of ABBV-722.
Dose normalized Cmax.
Dose normalized AUCs.
| Arm | Type | Description |
|---|---|---|
| Period 1 & 2 | EXPERIMENTAL | In Period 1, participants will receive a single dose of ABBV-722. In Period 2, participants will receive multiple daily doses of Itraconazole and a single dose of ABBV-722. |
| Period 1: Group 1 | EXPERIMENTAL | Participants will receive multiple doses of Upadacitinib |
| Period 1: Group 2 | EXPERIMENTAL | Participants will receive multiple doses of Upadacitinib |
| Period 2: Group 1 | EXPERIMENTAL | Participants will receive multiple doses of ABBV-722 |
| Period 2: Group 2 | EXPERIMENTAL | Participants will receive multiple doses of ABBV-722 |
| Period 3: Group 1 | EXPERIMENTAL | Participants will receive multiple doses of ABBV-722 and Upadacitinib |
| Period 3: Group 2 | EXPERIMENTAL | Participants will receive multiple doses of ABBV-722 and Upadacitinib |
| Period 1: Single Dose A | EXPERIMENTAL | Single dose will be administered under fasted conditions |
| Period 2: Single Dose A | EXPERIMENTAL | Single dose will be administered under fed (high-fat meal) conditions |
| Period 3: Single Dose B | EXPERIMENTAL | Single dose will be administered under fasted conditions |
| Part 1: Group 1 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose A or placebo. |
| Part 1: Group 2 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose B or placebo. |
| Part 1: Group 3 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose C or placebo. |
| Part 1: Group 4 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose TBD or placebo. |
| Part 1: Group 5 | EXPERIMENTAL | Participants will receive a single dose of either ABBV-722 Dose TBD or placebo. |
| Part 2: Group 6 | EXPERIMENTAL | Participants who are Han Chinese will receive a single dose of ABBV-722 Dose D. |
| Part 2: Group 7 | EXPERIMENTAL | Participants who are Japanese will receive a single dose of ABBV-722 Dose D. |
| Part 3: Group 8 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose E or placebo for 14 days. |
| Part 3: Group 9 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose F or placebo for 14 days. |
| Part 3: Group 10 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose A or placebo for 14 days. |
| Part 3: Group 11 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose G or placebo for 14 days. |
| Part 3: Group 12 | EXPERIMENTAL | Participants will receive either ABBV-722 Dose TBD or placebo for 14 days. |
| Name | Type | Description |
|---|---|---|
| ABBV-722 | DRUG | Oral Tablet |
| Itraconazole | DRUG | Oral Capsule |
| Midazolam | DRUG | Oral Solution |
| Metformin | DRUG | Oral Tablet |
| Digoxin | DRUG | Oral Tablet |
| Pitavastatin | DRUG | Oral Tablet |
| Sitagliptin | DRUG | Oral Tablet |
| Upadacitinib | DRUG | Oral |
| Placebo | DRUG | Oral Capsule |
Inclusion Criteria: * Laboratory values meet the criteria specified in the protocol. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG). Exclusion Criteria: * History of an...
ABBV-722 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with trials assessing how the drug moves through the body, its safety, tolerability, and effects when taken with food or other medications. It is not approved for any condition.
ABBV-722 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting Phase 1 clinical trials of this investigational small molecule in healthy adult participants.
ABBV-722 is in Phase 1 clinical development. All four registered trials are Phase 1 studies, with three completed and one active but not recruiting. The drug is investigational and has not been approved by regulatory authorities.
ABBV-722 has been studied in four Phase 1 trials. NCT06673238 assessed single and multiple ascending doses of oral capsules. NCT07361367 evaluated a tablet form with and without food. NCT07425899 studied ABBV-722 with upadacitinib. NCT07599761 is assessing the effect of itraconazole on ABBV-722.
ABBV-722 is being studied exclusively in healthy adult volunteers. All four Phase 1 trials enroll healthy participants aged 18 years and older, with no patient populations included. The studies are designed to evaluate the drug's pharmacokinetics, safety, and tolerability in this population.